Literature DB >> 7846017

Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.

M Yasue1, J Sakamoto, S Teramukai, T Morimoto, K Yasui, N Kuno, K Kurimoto, Y Ohashi.   

Abstract

Preoperative serum levels of carcinoembryonic antigen (CEA) and/or carbohydrate antigen 19.9 (CA19.9) were measured in 90 patients with advanced pancreatic cancer. CEA antigen was above the cutoff levels of 5.0 ng/ml in 51% of patients and CA19.9 was above the cutoff limit of 37 U/ml in 87% of patients. High preoperative CEA and CA19.9 levels were related to a poor prognosis of the patients. In multivariate analysis, the hazard rate was significantly higher in the high-CEA group (> 2.5 ng/ml) compared to the low-CEA group (< 2.4 ng/ml). An increase in CEA and/or CA19.9 within 1 month after the operation was also significantly related to the hazard rate. This study reconfirms the prognostic importance of preoperative and postoperative CEA and CA19.9.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846017     DOI: 10.1097/00006676-199411000-00011

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  19 in total

1.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.

Authors:  Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl
Journal:  Int J Gastrointest Cancer       Date:  2002

2.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 3.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

4.  Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma.

Authors:  Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2009-09-09       Impact factor: 3.452

5.  At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment.

Authors:  Eui Soo Han; Han Hong Lee; Jun Suh Lee; Kyo Young Song; Cho Hyun Park; Hae Myung Jeon
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

6.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

7.  CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.

Authors:  Clinton W Ali; Thomas F Kaye; Douglas J A Adamson; Iain S Tait; Francesco M Polignano; Martin S Highley
Journal:  J Gastrointest Cancer       Date:  2007

8.  Diagnosis of pancreatic cancer using serum proteomic profiling.

Authors:  Sudeepa Bhattacharyya; Eric R Siegel; Gloria M Petersen; Suresh T Chari; Larry J Suva; Randy S Haun
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

9.  Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

Authors:  Stephanie T Chang; Jacob M Zahn; Joe Horecka; Pamela L Kunz; James M Ford; George A Fisher; Quynh T Le; Daniel T Chang; Hanlee Ji; Albert C Koong
Journal:  J Transl Med       Date:  2009-12-11       Impact factor: 5.531

10.  Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.

Authors:  Darragh P O'Brien; Neomal S Sandanayake; Claire Jenkinson; Aleksandra Gentry-Maharaj; Sophia Apostolidou; Evangelia-Ourania Fourkala; Stephane Camuzeaux; Oleg Blyuss; Richard Gunu; Anne Dawnay; Alexey Zaikin; Ross C Smith; Ian J Jacobs; Usha Menon; Eithne Costello; Stephen P Pereira; John F Timms
Journal:  Clin Cancer Res       Date:  2014-06-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.